| Serial Number | 97388990 |
| Word Mark | PHENOTYPE LOCK |
| Filing Date | Friday, April 29, 2022 |
| Status | 732 - THIRD EXTENSION - GRANTED |
| Status Date | Thursday, October 23, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, March 19, 2024 |
| Goods and Services | Chemical and biological preparations for use in science and industry; Chemical and biological preparations for genetically modifying human and animal cells for non-medical purposes; reagents for use in the genetic modification of human and animal cells for scientific or medical research use; human and animal cells and parts in the nature of stem cells thereof for scientific and research purposes; T cells for scientific and research purposes; regulatory T cells for scientific and research purposes; preparations of blood or cells extracted from humans and animals for scientific and research purposes; chimeric antigen receptors and preparations thereof for scientific and research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use for use in science and industry; nucleic acids for laboratory use; synthetic deoxyribonucleic acids for scientific purposes; viral vectors for use in science and industry; nucleic acid vectors for use in science and industry |
| Goods and Services | Pharmaceutical manufacturing and processing; biological, biotechnological and biopharmaceutical manufacturing and manufacturing processing; manufacturing processing of biological tissue, blood, cell and genetic material; viral vector production, namely manufacture; gene therapy production, namely manufacture; custom manufacture of pharmaceutical and biological formulations and products; processing and modification of human and animal cells in the custom manufacture of pharmaceutical and biological formulations and products |
| Goods and Services | Pharmaceutical and biological preparations for diagnostic, medical, therapeutic and prophylactic use, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical, medical and veterinary preparations for diagnostic, therapeutic and prophylactic purposes, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical preparations for cell therapy; pharmaceutical preparations for gene therapy; pharmaceutical preparations for genetically modifying human and animal cells for diagnostic and medical purposes; human and animal cells and parts, namely stem cells thereof for medical and veterinary purposes; T cells for medical and veterinary purposes; regulatory T cells for medical and veterinary purposes; preparations of blood or cells extracted from humans and animals which have been adapted for therapeutic purposes; pharmaceutical, medical and clinical preparations for use in treatment, amelioration and prophylaxis of diseases, disorders and suppression of the immune system; immunological agents and preparations for medical purposes, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical preparations for therapies to modulate the immune system; pharmaceutical preparations for therapies for autoimmune conditions and immunological disorders; chimeric antigen receptors and therapeutic preparations for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical preparations for therapeutic delivery of nucleic acids; viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; medical pharmaceutical preparations containing viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; medical preparations containing nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, June 22, 2023 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, May 4, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, May 4, 2022 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Quell Therapeutics Limited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | London W120BZ GB |
| Party Name | Quell Therapeutics Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | London W120BZ GB |
| Event Date | Event Description |
| Tuesday, May 3, 2022 | NEW APPLICATION ENTERED |
| Wednesday, May 4, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, February 16, 2023 | ASSIGNED TO EXAMINER |
| Monday, February 27, 2023 | NON-FINAL ACTION WRITTEN |
| Monday, February 27, 2023 | NON-FINAL ACTION E-MAILED |
| Monday, February 27, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, May 19, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, May 19, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Saturday, May 20, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, June 22, 2023 | EXAMINERS AMENDMENT -WRITTEN |
| Thursday, June 22, 2023 | EXAMINERS AMENDMENT E-MAILED |
| Thursday, June 22, 2023 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Thursday, June 22, 2023 | EXAMINER'S AMENDMENT ENTERED |
| Thursday, June 22, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, June 23, 2023 | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED |
| Thursday, June 29, 2023 | ELECTRONIC RECORD REVIEW COMPLETE |
| Tuesday, July 11, 2023 | WITHDRAWN FROM PUB - OG REVIEW QUERY |
| Friday, July 21, 2023 | PREVIOUS ALLOWANCE COUNT WITHDRAWN |
| Tuesday, August 15, 2023 | NON-FINAL ACTION WRITTEN |
| Tuesday, August 15, 2023 | NON-FINAL ACTION E-MAILED |
| Tuesday, August 15, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, October 31, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, October 31, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, November 1, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, November 1, 2023 | FINAL REFUSAL WRITTEN |
| Wednesday, November 1, 2023 | FINAL REFUSAL E-MAILED |
| Wednesday, November 1, 2023 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Thursday, February 15, 2024 | EXAMINERS AMENDMENT -WRITTEN |
| Thursday, February 15, 2024 | EXAMINERS AMENDMENT E-MAILED |
| Thursday, February 15, 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Thursday, February 15, 2024 | EXAMINER'S AMENDMENT ENTERED |
| Thursday, February 15, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, February 28, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Wednesday, February 28, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, March 19, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, March 19, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, May 14, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Wednesday, June 5, 2024 | SOU TEAS EXTENSION RECEIVED |
| Wednesday, June 5, 2024 | SOU EXTENSION 1 FILED |
| Wednesday, June 5, 2024 | SOU EXTENSION 1 GRANTED |
| Thursday, June 13, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, March 21, 2025 | SOU TEAS EXTENSION RECEIVED |
| Friday, March 21, 2025 | SOU EXTENSION 2 FILED |
| Friday, March 21, 2025 | SOU EXTENSION 2 GRANTED |
| Saturday, March 22, 2025 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Thursday, October 23, 2025 | SOU TEAS EXTENSION RECEIVED |
| Thursday, October 23, 2025 | SOU EXTENSION 3 FILED |
| Thursday, October 23, 2025 | SOU EXTENSION 3 GRANTED |
| Thursday, October 23, 2025 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |